Physician profile
Edward D Kogan
NPI 1710994215
$939.68
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.87 · 2020: $210 · 2021: $62.71 · 2022: $652.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $210.44 | 2020 | |
| Novo Nordisk INC | $143.65 | 2022 | |
| Lilly USA, LLC | $119.00 | 2022 | |
| Janssen Pharmaceuticals, INC | $109.23 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.39 | 2022 | |
| Medtronic, INC. | $34.26 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $34.08 | 2022 | |
| Esperion Therapeutics, INC. | $28.45 | 2021 | |
| Pfizer INC. | $24.90 | 2022 | |
| Glaxosmithkline, LLC. | $23.32 | 2022 | |
| Dynavax Technologies Corporation | $19.46 | 2022 | |
| Opko Pharmaceuticals, LLC | $17.96 | 2022 | |
| Amgen INC. | $15.92 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.87 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.85 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $14.59 | 2022 | |
| Abbvie INC. | $12.31 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Kogan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.